CMS To Compare Anti-VEGF Drugs And Laser Treatments In MedCAC Review

CMS’ Medicare Evidence Development and Coverage Advisory Committee is scheduled to meet Sept. 21 to consider whether use of anti-VEGF drugs, including Roche’s Avastin (bevacizumab) and Roche/Genentech’s Lucentis (ranibizumab), are “reasonable and necessary” for treatment of diabetic macular edema.